Celltrion Healthcare, a biopharmaceutical company based in South Korea, has anno...
Gelesis, a company specializing in oral hydrogel technology, received FDA cleara...
Alopecia areata, the most prevalent form of alopecia affecting individuals of al...
Vertex Pharmaceuticals and Lonza have announced a strategic partnership to const...
Eli Lilly has set a benchmark in the oral obesity market by demonstrating a weig...
In 2020, the FDA rejected Intercept’s medicine and requested completion of a Pha...
Pfizer is set to discontinue one of its oral obesity drugs – namely lotiglipron ...
Pfizer’s Talzenna has received FDA approval as a second PARP inhibitor for prost...
A recent Phase 2 study conducted by Union Therapeutics has yielded positive resu...
The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disea...
Despite being best recognized for its biosimilars business, Coherus has been try...
The Food and Drug Administration (FDA) in the U.S. has rejected the U.K.-based F...
Colchicine was first used as a treatment for inflammation in Egypt more than 350...
AstraZeneca’s decision to abandon its remaining clinical candidate, AZD0186, mar...
AstraZeneca is partnering up with a self-identified “young” Chinese company to c...
Aldeyra Therapeutics has just shared results for its phase 3 trial, the INVIGORA...
